CA3072536A1 - Hpv vaccine - Google Patents

Hpv vaccine Download PDF

Info

Publication number
CA3072536A1
CA3072536A1 CA3072536A CA3072536A CA3072536A1 CA 3072536 A1 CA3072536 A1 CA 3072536A1 CA 3072536 A CA3072536 A CA 3072536A CA 3072536 A CA3072536 A CA 3072536A CA 3072536 A1 CA3072536 A1 CA 3072536A1
Authority
CA
Canada
Prior art keywords
sequence
conserved
seq
nucleic acid
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3072536A
Other languages
English (en)
French (fr)
Inventor
Lucy DORRELL
Joshua Blight
Arturo Reyes-Sandoval
Original Assignee
Oxford University Innovation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oxford University Innovation Ltd filed Critical Oxford University Innovation Ltd
Publication of CA3072536A1 publication Critical patent/CA3072536A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3072536A 2017-08-16 2018-08-16 Hpv vaccine Pending CA3072536A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1713163.2A GB201713163D0 (en) 2017-08-16 2017-08-16 HPV vaccine
GB1713163.2 2017-08-16
PCT/GB2018/052335 WO2019034887A1 (en) 2017-08-16 2018-08-16 HPV VACCINE

Publications (1)

Publication Number Publication Date
CA3072536A1 true CA3072536A1 (en) 2019-02-21

Family

ID=59895974

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3072536A Pending CA3072536A1 (en) 2017-08-16 2018-08-16 Hpv vaccine

Country Status (11)

Country Link
US (2) US11179456B2 (enExample)
EP (1) EP3668542A1 (enExample)
JP (1) JP7551495B2 (enExample)
KR (1) KR102713224B1 (enExample)
CN (1) CN111212659B (enExample)
AU (1) AU2018316734B2 (enExample)
CA (1) CA3072536A1 (enExample)
GB (1) GB201713163D0 (enExample)
MX (1) MX2020001655A (enExample)
SG (1) SG11202001244SA (enExample)
WO (1) WO2019034887A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201713163D0 (en) 2017-08-16 2017-09-27 Univ Oxford Innovation Ltd HPV vaccine
TWI852977B (zh) * 2019-01-10 2024-08-21 美商健生生物科技公司 前列腺新抗原及其用途
MX2022004484A (es) * 2019-10-16 2022-07-19 Cancer Research Tech Ltd Vector para el tratamiento de cancer.
EP4175664A2 (en) 2020-07-06 2023-05-10 Janssen Biotech, Inc. Prostate neoantigens and their uses
WO2022009049A1 (en) 2020-07-06 2022-01-13 Janssen Biotech, Inc. Prostate neoantigens and their uses
GB202019767D0 (en) 2020-12-15 2021-01-27 Chain Biotechnology Ltd Compostitions and methods
GB202209115D0 (en) 2022-06-21 2022-08-10 Chain Biotechnology Ltd Compositions and methods
WO2024218165A1 (en) * 2023-04-17 2024-10-24 Barinthus Biotherapeutics (Uk) Limited Hpv viral vector vaccine
WO2025092908A1 (zh) * 2023-11-01 2025-05-08 仁景(苏州)生物科技有限公司 治疗HPV感染相关疾病的mRNA疫苗
CN119464385B (zh) * 2024-12-04 2026-04-07 华中科技大学同济医学院附属同济医院 Matv11重组腺病毒载体、应用、制备方法及hpv治疗性疫苗
CN121950873A (zh) * 2026-01-28 2026-05-01 广东药科大学 一种融合基因及hpv核酸疫苗

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7026443B1 (en) 1999-12-10 2006-04-11 Epimmune Inc. Inducing cellular immune responses to human Papillomavirus using peptide and nucleic acid compositions
EP1732598A4 (en) * 2003-12-31 2009-08-26 Pharmexa Inc TRIGGERING CELLULAR IMMUNE RESPONSES TO THE HUMAN PAPILLOVIRUS USING PEPTIDE AND NUCLEIC ACID COMPOSITIONS
CN113559253B (zh) * 2007-11-02 2024-09-17 约翰霍普金斯大学 用于治疗或预防人乳头瘤病毒感染的多型hpv肽的组合物和方法
ES2464451T3 (es) 2008-02-21 2014-06-02 Delphi International Operations Luxembourg S.À R.L. Inyector de fuel con una disposición de control de válvula mejorada
CN102498217A (zh) 2009-04-20 2012-06-13 阿波维塔公司 Hpv的e6蛋白的特异性抗体及其应用
WO2014103608A1 (ja) 2012-12-25 2014-07-03 一般財団法人化学及血清療法研究所 HPV/HBsキメラタンパク質を有効成分とするHPV感染症及び／又はＢ型肝炎用ワクチン
WO2014165291A1 (en) 2013-03-12 2014-10-09 The Trustees Of The University Of Pennsylvania Improved vaccines for human papilloma virus and methods for using the same
WO2018060288A1 (en) 2016-09-29 2018-04-05 Glaxosmithkline Biologicals S.A. Compositions and methods of treatment of persistent hpv infection
GB201713163D0 (en) 2017-08-16 2017-09-27 Univ Oxford Innovation Ltd HPV vaccine

Also Published As

Publication number Publication date
US20220152189A1 (en) 2022-05-19
GB201713163D0 (en) 2017-09-27
AU2018316734B2 (en) 2025-08-21
AU2018316734A1 (en) 2020-02-27
CN111212659A (zh) 2020-05-29
US11179456B2 (en) 2021-11-23
JP2020536489A (ja) 2020-12-17
EP3668542A1 (en) 2020-06-24
MX2020001655A (es) 2020-08-17
SG11202001244SA (en) 2020-03-30
KR20200056384A (ko) 2020-05-22
WO2019034887A1 (en) 2019-02-21
KR102713224B1 (ko) 2024-10-07
US12064477B2 (en) 2024-08-20
JP7551495B2 (ja) 2024-09-17
CN111212659B (zh) 2023-09-22
US20200306358A1 (en) 2020-10-01

Similar Documents

Publication Publication Date Title
US12064477B2 (en) HPV vaccine
CN111088283B (zh) mVSV病毒载体及其病毒载体疫苗、一种基于mVSV介导的新冠肺炎疫苗
JP7098330B2 (ja) Ｈｐｖワクチン
KR101514473B1 (ko) 다중 유전자 발현용 벡터
US20110158952A1 (en) Compositions and methods for treating human papillomavirus-mediated disease
US20220160853A1 (en) Cancer vaccine compositions and methods for use thereof
TW200840869A (en) Papillomavirus vaccine
CN104039833A (zh) 针对hpv的疫苗
KR20090005010A (ko) Ｈｐｖ-18-기재의 유두종바이러스 백신
KR20090005011A (ko) Ｈｐｖ-16-기재의 유두종바이러스 백신
JP2006503914A5 (enExample)
CA3181431A1 (en) A recombinant modified vaccinia virus ankara (mva) vaccine against coronavirus disease
US20140024017A1 (en) IDENTIFICATION OF A NOVEL HUMAN POLYOMAVIRUS (IPPyV) AND APPLICATIONS
WO2024218165A1 (en) Hpv viral vector vaccine
CN102649963B (zh) 可用于食管癌防治的基于hpv l1基因的重组腺病毒
US11154613B2 (en) HCV vaccines
Bettina et al. A chimeric L1-L2 virus-like particle (VLP) vaccine targeting common cutaneous human papillomavirus type 1 (HPV1)
JP2024518565A (ja) 組換え重複ペプチド及びネイティブタンパク質を含むワクチン製剤
CN121627808A (zh) Hpv-52型e6蛋白的特异性ctl表位肽及其应用
EP2598520A2 (en) Recombinant proteins as vaccines for protection against disease induced by infection with mink astrovirus

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20230816

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240802

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20240802

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240802

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20240912

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20250113

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250213

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250620

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250620

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260226

U13 Renewal or maintenance fee not paid

Free format text: ST27 STATUS EVENT CODE: N-2-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE

Effective date: 20260427